Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC)

Llovet, J; Merle, P; Weiss, KH; Yau, T; Ross, P; Mazzaferro, V; Blanc, JF; Ma, Y; Yen, C; Kocsis, J; Choo, S; Sukeepaisarnjaroen, W; Gerolami, R; Dufour, Jean-François; Gane, E; Ryoo, BY; Peck, M; Dao, T; Yeo, W; Lamlertthon, W; ... (November 2016). Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC). Hepatology, 64(1Suppl), 621A-621A. Wiley Interscience

Item Type:

Conference or Workshop Item (Abstract)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie

UniBE Contributor:

Dufour, Jean-François

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0270-9139

Publisher:

Wiley Interscience

Language:

English

Submitter:

Lilian Karin Smith-Wirth

Date Deposited:

11 Apr 2017 16:40

Last Modified:

11 Apr 2017 16:40

URI:

https://boris.unibe.ch/id/eprint/94070

Actions (login required)

Edit item Edit item
Provide Feedback